horizon therapeutics public limited company

The directors of Horizon accept responsibility for the information contained in this announcement relating to Horizon, the Horizon group, directors of Horizon and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the directors of Amgen and Acquirer Sub (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information. The directors of Amgen and Acquirer Sub accept responsibility for the information contained in this announcement other than that relating to Horizon, the Horizon group, directors of Horizon and members of their immediate families, related trusts and persons connected with them. Statements Required by the Irish Takeover Rules

Amended 2011 Equity Incentive Plan, the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan, the Horizon Pharma Public Limited Company Amended and Restated 2014 Equity Incentive Plan, the Horizon Therapeutics Public Limited Company Amended and Restated 2018 Equity Incentive Plan and the Horizon Therapeutics Public Limited Company Amended and Restated 2020 Equity Incentive Plan (each a 'Horizon Equity Award Holder') and (ii) participants in the Horizon Therapeutics plc 2020 Employee Share Purchase Plan (each a 'Horizon ESPP Participant'), has been sent to the Horizon Equity Award Holders and the Horizon ESPP Participants in connection with the Proposed Transaction. In accordance with Rule 15 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the 'Irish Takeover Rules'), Amgen and Horizon announce that a joint letter, dated January 27, 2023, containing details of the proposal (the 'Proposal') to (i) equity award holders under the Horizon Pharma, Inc. DUBLIN - Horizon Therapeutics plc (NASDAQ: HZNP), On December 12, 2022, the board of directors of Horizon Therapeutics plc, a public limited company incorporated in Ireland (the 'Company' or 'Horizon') and the board of directors of Amgen Inc., a Delaware corporation, announced that they had reached agreement on the terms of a cash offer for the Company by Pillartree Limited, a newly formed private limited company wholly owned by Amgen, pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of the Company.Īs outlined in that announcement, the Proposed Transaction is to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 (the 'Scheme').

Horizon therapeutics public limited company